Clinical trials

 
 
Clinical.jpg
 

Our Commitment to Patients
With Progesterone Receptor Positive (PR+) Cancers

At Context Therapeutics, we are passionate about improving health and committed to helping people with cancer. To fulfill our promise to patients, we have created the ONWARD Clinical Trial network to evaluate our investigational product Apristor (onapristone ER).

 
PR+ Rare Ovarian Cancers

PR+ Rare Ovarian Cancers

 
PR+ Endometrial Cancer

PR+ Endometrial Cancer

 
PR+, ER+, HER2- Breast Cancer

PR+, ER+, HER2- Breast Cancer

 
 

ONWARD 201

Phase 2 Trial in ER+, PR+, HER2- Breast Cancer

ONWARD 201 will evaluate Apristor + Faslodex in second line (2L) metastatic breast cancer patients who are ER+, PR+, HER2- and who have failed first line Cdk4/6 inhibitor plus antiestrogen combination therapy.

To learn more →

ONWARD 203 / ONAWA

Window of Opportunity Trial in PR+ Breast Cancer

ONWARD 203 will evaluate Apristor in a presurgical, window of opportunity study in treatment naive PR+ breast cancer patients.

To learn more →

 

ONWARD 220

Phase 2 Basket Trial in PR+ Gynecologic Cancers

ONWARD 220 will evaluate Apristor in 2L/3L chemotherapy resistant uterine (endometrial) and ovarian (low grade serous, granulosa) cancer patients.

To learn more →

ONWARD 221

Phase 2 Trial in ER+, PR+ Endometrial Cancer

ONWARD 221 will evaluate Apristor + Aromasin in patients with advanced endometrial cancer.

To learn more →

 

Investigator Sponsored Trials

Join our Investigator Network

At Context Therapeutics, we are committed to the advancement of medical and scientific knowledge that addresses the unmet needs of patients with hormone driven cancers.  

Submit an IST →

 
 

PHYSICIANS: Click here to learn more about the trial on ClinicalTrials.gov, including eligibility criteria, locations and contacts.

Our Science

Developing the next generation of antihormonal therapies to treat ovarian, endometrial, and breast cancers.

Go

Our Pipeline

Apristor is an investigational new medicine for progesterone receptor positive (PR+) ovarian, endometrial, and breast cancers.

Go